Open access · CC-BY
via OpenAlex
SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis
Kayvan Zainabadi, Cassie J. Liu, Alison L. M. Caldwell, Leonard Guarente
PLoS ONE · 2017 · ▲ 117 citations
Abstract
Overexpression or pharmacological activation of SIRT1 has been shown to extend the lifespan of mice and protect against aging-related diseases. Here we show that pharmacological activation of SIRT1 protects in two models of osteoporosis. Ovariectomized female mice and aged male mice, models for post-menopausal and aging-related osteoporosis, respectively, show significant improvements in bone mass upon treatment with SIRT1 agonist, SRT1720. Further, we find that calorie restriction (CR) results in a two-fold upregulation of sirt1 mRNA expression in bone tissue that is associated with increased bone mass in CR mice. Reciprocally, SIRT1 whole-body knockout (KO) mice, as well as osteoblast and osteoclast specific KOs, show a low bone mass phenotype; though double knockout mice (containing SIRT1 deleted in both osteoblasts and osteoclasts) do not show a more severe phenotype. Altogether, these findings provide strong evidence that SIRT1 is a positive regulator of bone mass and a promising target for the development of novel therapeutics for osteoporosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1371/journal.pone.0185236
- Canonical
- link ↗
- Fetched
- 2026-10-18 MST
Cite this
APA
Zainabadi, K., Liu, C.J., Caldwell, A.L.M., & Guarente, L. (2017). SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. <em>PLoS ONE</em>. https://doi.org/10.1371/journal.pone.0185236
Vancouver
Zainabadi K, Liu CJ, Caldwell ALM, Guarente L. SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS ONE. 2017. doi:10.1371/journal.pone.0185236.
BibTeX
@article{kayvan2017SIRTis,
title = {SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis},
author = {Kayvan Zainabadi and Cassie J. Liu and Alison L. M. Caldwell and Leonard Guarente},
journal = {PLoS ONE},
year = {2017},
doi = {10.1371/journal.pone.0185236},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Endocrinology and Metabolism Clinics of North America 2012
Citation only
Pathophysiology of Osteoporosis
Frontiers in Cell and Developmental Biology 2020
Open access · CC-BY
The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
Elsevier eBooks 2021
Citation only
Osteoporosis and bone loss
Endocrinology and Metabolism Clinics of North America 2005
Citation only
Pathophysiology of Age-Related Bone Loss and Osteoporosis
Clinical Therapeutics 2015
Citation only
The Pathophysiology and Treatment of Osteoporosis
Transfusion and Apheresis Science 2008
Citation only